Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3903 Comments
786 Likes
1
Xion
Regular Reader
2 hours ago
I feel like I should tell someone about this.
👍 16
Reply
2
Shady
Engaged Reader
5 hours ago
Could’ve avoided a mistake if I saw this sooner.
👍 14
Reply
3
Ahmias
Loyal User
1 day ago
I read this and now I’m thinking too much.
👍 108
Reply
4
Garn
Registered User
1 day ago
This feels like a missed opportunity.
👍 13
Reply
5
Nylani
Power User
2 days ago
Anyone else just realized this?
👍 153
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.